Table 3.

Subsequent therapy

	All patients receiving subsequent treatment (n = 38)
IMiD-based regimen, n (%)
Pomalidomide-dexamethasone	15 (39)
Pomalidomide-cyclophosphamide-dexamethasone	6 (16)
Pomalidomide-prednisone	2 (5)
Lenalidomide-cyclophosphamide-prednisone	2 (5)
CELMoD-based regimen, n (%)
Iberdomide ± dexamethasone	10 (26)
PI-based regimen, n (%)
Bortezomib-cyclophosphamide-dexamethasone	1 (3)
Carfilzomib-dexamethasone	1 (3)
IMiD + monoclonal antibody, n (%)
Elotuzumab-pomalidomide-dexamethasone	1 (3)